TY  - GEN
AU  - Desai, Milind Y
AU  - Owens, Anjali T
AU  - Abraham, Theodore
AU  - Olivotto, Iacopo
AU  - Garcia-Pavia, Pablo
AU  - Lopes, Renato D
AU  - Elliott, Perry
AU  - Fernandes, Fabio
AU  - Verheyen, Nicolas
AU  - Maier, Lars
AU  - Meder, Benjamin
AU  - Azevedo, Olga
AU  - Kitaoka, Hiroaki
AU  - Wolski, Kathy
AU  - Wang, Qiuqing
AU  - Jaber, Wael
AU  - Mitchell, Lisa
AU  - Myers, Jonathan
AU  - Rano, Thomas
AU  - Gong, Zhiqun
AU  - Zhong, Yue
AU  - Carter-Bonanza, Suzanne
AU  - Florea, Victoria
AU  - Aronson, Ron
AU  - Nissen, Steven E
PY  - 2025
UR  - https://hdl.handle.net/20.500.12105/27053
AB  - Mavacamten is approved to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). However, its effects in nonobstructive HCM remain uncertain. We conducted a phase 3, international, double-blind, placebo-controlled, clinical trial...
LA  - eng
PB  - Massachusetts Medical Society
TI  - Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.
TY  - research article
ER  -